Twelfth Annual Meeting of the American Society of Preventive Oncology

March 14-15, 1988

Hyatt Regency Bethesda

Bethesda, Maryland
# MASTER AGENDA

## Monday, March 14

### MORNING
- Registration  
  7:30 am - 6:00 pm
- Opening Welcome  
  8:30 am - 9:00 am
- Poster Session Open  
  9:00 am - 6:00 pm
- Symposium -  
  Biochemical Markers of Colorectal Cancer  
  9:00 am - 12:30 pm

### AFTERNOON
- Submitted Papers  
  1:30 pm - 2:30 pm
- Symposium -  
  Recently Complete Etiologic Studies of Colorectal Neoplasms  
  2:30 pm - 5:00 pm

### EVENING
- Symposium  
  Issues and Recommendations in the Early Detection of Colorectal Cancer  
  5:00 pm - 6:00 pm
- Business Meeting  
  6:00 pm - 7:00 pm

## Tuesday, March 15

### MORNING
- Registration  
  7:30 am - 5:00 pm
- Welcoming Remarks and Presentation of Distinguished Achievement Award  
  8:15 am - 8:40 am
- Poster Session Open  
  8:15 am - 5:00 pm
- Symposium -  
  Strengths and Limitations of Methodologic Approaches to the Study of Diet and Cancer  
  8:40 - 12:00 pm

### AFTERNOON
- Submitted Papers  
  1:20 pm - 2:40 pm
- Symposium -  
  Priorities/Barriers in Cancer Prevention and Control  
  2:40 pm - 5:00 pm

### EVENING
- Reception  
  6:30 pm - 7:30 pm
- Banquet  
  "Cancer Prevention: A Risky Business"  
  Dr. Vincent DeVita,  
  7:30 - 10:30 pm
- Adjourn
PROGRAM AND SELECTED PAPERS

Welcome to Bethesda

Joseph Cullen, Ph.D.
Program Chairpersons: Susan Preston-Martin, Ph.D.
George Roush, M.D.

sponsored by:
American Society of Preventive Oncology
National Cancer Institute
ASPO

In its twelfth year ASPO is striving to:

- promote the exchange and dissemination of information and ideas relating to cancer prevention and control;
- identify and stimulate research areas in cancer prevention and control;
- foster the implementation of programs in cancer prevention and control.

A growing and active membership facilitates achievement of these goals. The Executive Committee and council members listed below are very interested in hearing from prospective or current members.

Anthony B. Miller, M.B., F.R.C.P.
Department of Preventive Medicine & Biostatistics
McMurrich Building, 4th Floor
University of Toronto
Toronto, Ontario
Canada M5S 1A8
(416)978-5662

Virginia L. Ernster, Ph.D.
University of California
Dept. of Epidemiology & International Health
San Francisco, CA 94143
(415)476-1424

Nicholas L. Petrakis, M.D.
University of California
Dept. of Epidemiology & International Health
1699 HSW
San Francisco, CA 94143
(415)476-2001

Marie Swanson, PhD, MPH
Director, Division of Epidemiology
Michigan Cancer Foundation
110 E. Warren
Detroit, MI 48201
(313)833-0710, Ext. 269

David Schottenfeld, M.D.
Chairman & Professor
Department of Epidemiology
School of Public Health
University of Michigan
109 Observatory St.
Ann Arbor, MI 48109-2029
(313)764-5435

Robert Day, MD
Director of the Fred Hutchinson Cancer Research Center
1124 Columbia St.
Seattle, WA 98104
(206)467-4302 or (206)467-5000

Virginia L. Ernster, Ph.D.
University of California
Dept. of Epidemiology & International Health
San Francisco, CA 94143
(415)476-1424

Marie Swanson, PhD, MPH
Director, Division of Epidemiology
Michigan Cancer Foundation
110 E. Warren
Detroit, MI 48201
(313)833-0710, Ext. 269

Robert Day, MD
Director of the Fred Hutchinson Cancer Research Center
1124 Columbia St.
Seattle, WA 98104
(206)467-4302 or (206)467-5000

George C. Roush, MD
Director
Division of Epidemiologic Research
PMI/Strang Clinic
55 E. 34th Street
New York, NY 10016
(212) 684-6969
Guy R. Newell, M.D.
University of Texas System Cancer Center
Texas Medical Center
Houston, TX 77030
(713)792-3020

John H. Weisburger, Ph.D.
American Health Foundation
Valhalla, N.Y. 10595
(914)592-2600, Ext. 302

Charles Key, M.D., Ph.D.
Department of Pathology
University of New Mexico
School of Medicine
900 Camino de Salud NE
Albuquerque, New Mexico 87131
(505)277-5541

Louise A. Brinton, Ph.D.
Environmental Epidemiology Branch
National Cancer Institute
7910 Woodmont Ave.
Landow Bldg. - Rm. 3C06
Bethesda, MD 20892
(301)496-1691

Richard R. Love, M.D.
Cancer Prevention Program
1300 University Ave. - 7C
Madison, WI 53706
(608)263-7066

W. Thomas London, M.D.
Institute for Cancer Research
7701 Burholme Ave.
Philadelphia, PA 19111
(215)728-2203

Joseph F. Fraumeni, Jr., M.D.
Environmental Epidemiology Branch
National Cancer Institute
Landow Bldg.
7910 Woodmont Ave.
Bethesda, MD 20205
(301)496-1691

Former Presidents:

Nicholas Petrakis, M.D.

Joseph F. Fraumeni, Jr., M.D.

Daniel G. Miller, M.D.
PMI-Strang Clinic
55 E. 34th Street
New York, NY 10016
(212) 683-1000

Anthony B. Miller, M.B., F.R.C.P.

Nathaniel L. Berlin, M.D.
Deputy Director
Papanicolaou Comprehensive
Cancer Center
University of Miami
School of Medicine
P.O. Box 016960 (D8-4)
Miami, FL 33101
(305) 348-4810

The National Office for ASPO is at the University of Wisconsin, where the
executive secretary, Carrie Fassil, may be contacted for any information or
assistance: 1300 University Ave. - 7C, Madison, WI 53706, (608) 263-6919.
Messages

Please see Carrie Fassil at the registration desk if you expect or wish to leave a message.

Banquet

Please let Carrie Fassil know immediately of your plans to attend the banquet on Monday evening, if you have not already done so.

Special acknowledgement

The Executive Committee of ASPO wishes to offer special thanks to Drs. Joseph Cullen, Susan Preston-Martin, and George Roush, the program chairpersons for their tireless efforts in arranging this meeting.
Monday, March 14

7:30 am - 6:00 pm
BALLROOM FOYER
REGISTRATION

8:50 am - 9:00 am
OPENING WELCOME: David Schottenfeld, MD, President, ASPO

9:00 am - 6:00 pm
HAVERFORD
/BACCARAT ROOM
POSTER SESSION OPEN

9:00 am - 12:30 pm
HAVERFORD
/BACCARAT ROOM
SYMPOSIUM
Biochemical Markers of Colorectal Cancer
Moderator: Gail E. McKeown-Eyssen, PhD
Studies of Fecal Mutagenicity in Humans
Mark H. Schiffman, MD, MPH
Calcium and Measures of Cell Proliferation
Michael J. Wargovich, PhD
Ornithine Decarboxylase
Gordon D. Luk, MD, PhD

10:15 am - 10:30 am
REFRESHMENT BREAK

Adenosine Diphosphate Ribosyl Transferase as an Indicator of Oxidative Stress
Ronald W. Pero, PhD
Oncogenes and Markers of Signal Transduction
I. Bernard Weinstein, MD
Discussant
Alfred I. Neugut, MD, PhD
Panel Discussion

12:30 pm - 1:30 pm
LUNCH

1:30 pm - 2:30 pm
SUBMITTED PAPERS
Moderator: George C. Roush, MD

* 1
Mammography Utilization Patterns In A Cohort of High Risk Women
Lisa Begg, R.N., DrPH

* Number refers to the abstract printed in the selected paper section of this program.
2:30 pm - 5:00 pm
HAVERFORD / BACCARAT ROOM

**SYMPOSIUM**
Recently Complete Etiologic Studies of Colorectal Neoplasms
Moderator: John D. Potter, MBBS, PhD
Collaborative Case-Control Study of Colorectal Cancer in Chinese and Chinese Americans
Alice S. Whittemore, PhD
Case-Control Study of Colon Cancer in Los Angeles County
Ruth A. Peters, ScD

3:30 pm - 3:50 pm
REFRESHMENT BREAK

5:00 pm - 6:00 pm
SYMPOSIUM
Issues and Recommendations in the Early Detection of Colorectal Cancer
Discussants
Anthony B. Miller, MB, FRCP
Jack S. Mandel, PhD, MPH

6:00 pm - 7:00 pm
HAVERFORD / BACCARAT ROOM

**BUSINESS MEETING**

**AGENDA** (12th Annual Meeting)
David Schottenfeld, President presiding
Report of the President Dr. Schottenfeld
Report of the Secretary/Treasurer Dr. Love
Report of the Auditors (appended) Dr. Love
Report of the Nominating Committee
Secretary/Treasurer: Dr. Ernster
Director(s):

* Number refers to the abstract printed in the selected paper section of this program.
Tuesday, March 15

7:30 am - 5:00 pm
BALLROOM FOYER
REGISTRATION

8:15 am - 5:00 pm
HAVENFORD /BACCARAT ROOM
POSTER SESSION OPEN

8:15 am
WELCOMING REMARKS AND PRESENTATION OF DISTINGUISHED ACHIEVEMENT AWARD
David Schottenfeld, MD
President, ASPO

8:25 am - 3:40 am
AWARDEE ADDRESS

8:40 am - 12:00 pm
HAVENFORD /BACCARAT ROOM
SYMPOSIUM
Strengths and Limitations of Methodologic Approaches to the Study of Diet and Cancer
Moderator: Peter Greenwald, MD, DrPH
Validity of International Migration and Time Trend Studies
Ross Prentice, PhD
Validity of Case-Control and Cohort Studies of Dietary Fat and Breast Cancer
Barbara S. Hulka, MD, MPH

9:40 am - 10:00 am
REFRESHMENT BREAK
Clinical Metabolic Studies
Philip Taylor, MD
Clinical Trials
David P. Byar, MD
Summary and Future Perspectives
Peter Greenwald, MD, DrPH
Panel Discussion

12:00 pm - 1:20 pm
LUNCH

1:20 pm - 2:40 pm
SUBMITTED PAPERS
Moderator: Susan Preston-Martin, PhD
* 4 Recruitment Strategies For Cancer Prevention Trials
   Thomas E. Moon, PhD

* 5 Cancer Control Research in Defined Populations:
   Design and Methodologic Considerations
   Bruce Trock, PhD

* 6 Analysis of Barriers and Incentives to Mammographic
   Screening in the American Cancer Society (ACS) 1987
   Texas Breast Screening Project (TBSP)
   Victor G. Vogel, MD, MHS

* 7 Using a Population-based Cancer Registry For
   Recruitment in a Cancer Control Study: The Wisconsin
   Tamoxifen Study
   Polly A. Newcomb, PhD

2:40 pm - 5:00 pm

SYMPOSIUM
Priorities/Barriers in Cancer Prevention and Control

Moderator: Edward Sondik, PhD

Priorities
David M. Eddy, MD, PhD

Economic and Organizational Barriers
Edward H. Wagner, MD, MPH

3:30 pm - 3:45 pm

REFRESHMENT BREAK

Communications Barriers
Erwin Bettinghaus, PhD

Compliance Barriers
Kelly D. Brownell, PhD

Panel Discussion

6:30 pm - 7:30 pm

RECEPTION

7:30 pm - 10:30 pm

BALLROOM FOYER

BANQUET
Cancer Prevention: A Risky Business
Vincent T. DeVita, Jr., M.D.

ADJOURNMENT

* Number refers to the abstract printed in the selected paper
  section of this program.
INVITED SPEAKERS
Ronald W. Pero, PhD
Department of Biochemistry
PMI/Strang Clinic
New York, New York

Ruth A. Peters, ScD
Department of Preventive Medicine
University of Southern California
Los Angeles, California

John D. Potter, MBBS, PhD
Division of Epidemiology
School of Public Health
Minneapolis, Minnesota

Ross Prentice, PhD
Cancer Surveillance System
Fred Hutchinson Cancer Research Center
Seattle, Washington

Mark H. Schiffman, MD, MPH
Environmental Epidemiology Branch
National Cancer Institute
Bethesda, Maryland

Edward Sondik, PhD
Division of Cancer Prevention and Control
Surveillance and Operations Research Branch
National Cancer Institute
Bethesda, Maryland

Philip Taylor, MD
Division of Cancer Prevention and Control
Cancer Prevention Studies Branch
National Cancer Institute
Bethesda, Maryland

Edward H. Wagner, MD, MPH
Center for Health Studies
Group Health Cooperative
Seattle, Washington

Michael J. Wargovich, PhD
Section of GI Oncology
M.D. Anderson Hospital
Houston, Texas

Alice S. Whittemore, PhD
Department of Family, Community, and Preventive Medicine
Stanford University Medical Center
Stanford, California

Walter Willett, MD
Channing Laboratory
Boston, Massachusetts

Erwin Bettinghaus, PhD
College of Communication Arts and Sciences
Michigan State University
East Lansing, Michigan

Kelly D. Brownell, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

Randall W. Burt, MD
Division of Gastroenterology
Department of Internal Medicine
University of Utah
Salt Lake City, Utah

David P. Byar, MD
Division of Cancer Prevention and Control
National Cancer Institute
Bethesda, Maryland

David M. Eddy, MD, PhD
Center for Health Policy Research and Education
Durham, North Carolina

Peter Greenwald, MD, DrPH
Division of Cancer Prevention and Control
National Cancer Institute
Bethesda, Maryland

Barbara S. Hulka, MD, MPH
School of Public Health
University of North Carolina
Chapel Hill, North Carolina

Gordon D. Luk, MD, PhD
Division of Gastroenterology
Harper Hospital
Wayne State University
Detroit, Michigan

Jack S. Mandel, PhD, MPH
Division of Environmental and Occupational Health
University of Minnesota
Minneapolis, Minnesota

Gail E. McKeown-Eyssen, PhD
Department of Preventive Medicine and Biostatistics
University of Toronto
Toronto, Ontario, Canada

Anthony B. Miller, MB, FRCP
Epidemiology Unit
National Cancer Institute of Canada
University of Toronto
Toronto, Ontario, Canada

Alfred I. Neugut, MD, PhD
Department of Medicine and Public Health
Columbia University College of Physicians and Surgeons
New York, New York
SELECTED PAPERS

Mammography Utilization Patterns In A Cohort Of High Risk Women

Lisa Begg, R.N., Dr.P.H.
Jackie Dunbar, R.N., Ph.D.
Steve Belle, Ph.D.
Joyce Yasko, R.N., Ph.D.

Department of Epidemiology
Graduate School of Public Health
University of Pittsburgh
Pittsburgh, PA 15261

School of Nursing
Victoria Building
University of Pittsburgh
Pittsburgh, PA 15261
Mammography Utilization Patterns in A Cohort of High Risk Women

Breast cancer is known to aggregate in families. A family registry with the Pittsburgh area was established as a mechanism to ascertain breast cancer detection practices in a group of healthy women at increased risk of breast cancer. (1) Data were obtained through a longitudinal registry of first-degree female relatives of 1,548 breast cancer patients treated at three area hospitals. All patients were confirmed to have histologically-proven breast cancer. Written informed consent was obtained from each patient and their relatives. Questionnaires were administered via phone to determine the baseline frequency of mammography, professional and self-breast examinations. A follow-up phone interview, at one year, was obtained to determine changes in baseline practices.

Seven-hundred-eighty-nine relatives, aged 35 and above, were interviewed. Only relatives of this age were chosen because of the policy recommendation on screening mammograms put forth by such national groups as the American Cancer Society, National Cancer Institute, and American Medical Association. (2) There were 487 sisters, 225 daughters and 77 mothers of breast cancer patients in this cohort. In terms of mammography utilization, 57% of relatives had had at least one mammogram with no difference (58% of sisters, 57% of mothers and 56% of daughters) by relative status.

Because the recommendations for repeat mammography vary with age, we evaluated the 470 relatives who were age 50 and older at baseline interview. The policy recommendations for this age group call for mammograms to be repeated on an annual basis. (2) Follow-up data was available for 91.50% of these relatives (n=430) and showed no differences in response rates by relative status or hospital. Of these 430 relatives, 294 (68%) women overall reported
having had at least one mammogram. The rates by relative status were not statistically different, ranging from 67% of the sisters to 72% of the mothers. Of those women who reported never having had a mammogram at baseline, 26% reported doing so in the one-year follow-up period. If the entire sample is evaluated for relatives aged 35 and older who have never had a mammogram, only 27% report obtaining a mammogram within the previous year. Thus, it appears that age, relative status and locations within an urban area do not influence these relatives to obtain screening mammography. While simple education and advice can improve mammography utilization rates by enrolling 27% of those women never screened, a substantial number of women at high risk of breast cancer do not avail themselves to this procedure. Thus, more intensive efforts need to be directed toward those high risk women to promote increased utilization of this efficacious procedure.

REFERENCES


A CASE-CONTROL STUDY OF SOFT-TISSUE SARCOMA:
FARMING AND PESTICIDE USE


1- Epidemiology and Biostatistics Program, National Cancer Institute,
Landow Building-4C16, Bethesda, MD 20892.

2- Cancer Data Service, University of Kansas Medical Center.

3- Division of Biology, Kansas State University.
Reports from Sweden, Denmark, Italy, and the United States have suggested that persons exposed to herbicides have up to a sixfold excess risk of soft-tissue sarcoma (STS) (1-8). A population-based case-control study was conducted in Kansas to examine the relationship between exposure to pesticides and the development of soft-tissue sarcoma (STS). Data from telephone interviews with 133 STS cases and 948 controls, or their next-of-kin, did not show any association between STS and agricultural use of herbicides (Odds ratio [OR] = 0.9; 95% CI= 0.5,1.6). STS was associated with insecticide use on animals (OR=1.6; 95% CI=0.9,2.5) but not on crops (OR=0.8; 95% CI=0.4,1.6). STS risk was higher among farmers who themselves mixed or applied insecticides to animals (OR=1.7; 95% CI=1.0,2.9) than among farmers who had someone else do these tasks (OR=1.1; 95% CI=0.4,2.6). Farmers who failed to use any protective equipment to reduce insecticide exposure were at significantly elevated risk of STS (OR=1.9; 95% CI=1.1,3.3). Risk rose with early calendar year of first use, even after adjustment for duration of insecticide use. The duration- and age-adjusted ORs for STS among farmers who first used insecticides after 1965, during 1956-1965, 1946-1955, and prior to 1946 were 1.0 (referent category), 0.3 (95% CI=0.01,4.7), 2.6 (95% CI=0.3,26.7), and 4.9 (95% CI=0.6,64.1), respectively. The excess risk appeared to be primarily among fibrous and myosarcomatous sarcomas with no or little association seen for lipomatous or other STS neoplasms. Myosarcomatous sarcomas increased significantly with time since first use of insecticides on animals. If the reported association between STS and insecticides is causal,
these data suggest that exposure to the agent(s) responsible may have been reduced in the mid 1950s, for example, by changing insecticides or by increasing mechanization of dairy farming, or have an average latent period for STS of at least 20 years.


STUDIES ON BARRETT'S ESOPHAGUS: A UNIQUE METAPLASTIC PREMALIGNANT LESION FOR ADENOCARCINOMA

H. Garewal, M.D., Ph.D., R. Prabhala, M.S., D. Sloan, M.S., R. Sampliner, M.D.

Veteran Administration Medical Center and University of Arizona Health Sciences Center, 3601 S. 6th Avenue, Tucson, Arizona 85723

Barrett's esophagus (BE) is a condition in which metaplastic columnar epithelium replaces the normal squamous lining of the esophagus. It is a premalignant lesion associated with an increased risk of esophageal adenocarcinoma (2). We have used BE as a model lesion for laboratory and clinical studies of adenocarcinoma premalignancy. Epithelial cell cultures were established from endoscopic biopsies of Barrett's mucosa. Six cultures have been karyotyped; 2 of the 6 showed clonal cytogenetic abnormalities. The effect of retinoids, carotenoids and ornithine decarboxylase (ODC) inhibitors on the growth of the cultured cells was studied. The drugs used were 13-cis retinoic acid (RA), 4-hydroxyphenylretinamide (4-HPR), beta carotene (BC), canthaxanthene (C) and L-difluoromethylornithine (DFMO). Methods used were quantitation of
cell number, the ATP drug sensitivity assay developed in our laboratory and colony formation. Continuous drug exposure was used with concentrations of $10^{-9}$ to $10^{-6}$ M for RA, 4-HPR, BC and C; 0.05 to 5 for DFMO. The retinoids and carotenoids did not have significant inhibitory effects on growth except at the highest concentrations (10$^{-6}$ and 10$^{-7}$ M) which resulted in approximately 50% inhibition. This is consistent with the results of our clinical study of RA in BE. The trial was initiated because of the known activity of RA in other premalignant conditions (1). Thus far, 13 patients have been treated with RA with no responses. In contrast to the in vitro results with retinoids and carotenoids, DFMO had an inhibitory effect on growth cultured cells even at the lowest concentration tested (60% growth of 0.05 mM) with >50% inhibition at 0.5 and 5 mM. Consequently, inhibition of ODC may have a role in the treatment of this disease. A clinical trial with DFMO is planned. This cell culture system should prove valuable in studying the characteristics of premalignant cells and screening agents for activity against premalignant lesions.

REFERENCES


Recruitment Strategies For Cancer Prevention Trials

Thomas E. Moon, Ph.D., Madelyn L. Ferro, B.A.,
Norman E. Levine, M.D.

Department of Family and Community Medicine, Internal Medicine and
the Arizona Cancer Center, University of Arizona, 1501 N. Campbell
Ave., Tucson, Arizona, 85724
Recruitment Strategies For Cancer Prevention Trials

Thomas E. Moon, Ph.D., Madelyn L. Ferro, B.A.,
Norman E. Levine, M.D.

University of Arizona, College of Medicine, Tucson, Arizona 85724

Recruitment for cancer prevention studies may be impacted by the strategy used to identify subjects. Between October 1985 through September 1987, strategies were evaluated to recruit subjects for 2 related trials evaluating vitamin A compounds in prevention of skin cancer. Strategies included physician referral and use of print, radio and TV media, and referral by spouse/friend. People willing to participate were screened using a common protocol and asked how they heard of the trials. Of 875 inquiries during the 24 months, 44% were screened with 23% enrolled. Extent of community physician involvement and amount of regular medical care used by subjects affected recruitment strategies. Type of strategy did effect recruitment. Use of media (paid advertisements plus articles/interviews) was effective in recruiting 43% and 87% of subjects for the 2 trials, costing $3 and $47 per subject enrolled. Physician referral accounted for the remaining 13% and 57% of recruitment, costing $78 per subject. Referral by spouse/friend was unsuccessful as a strategy. Factors related to media success include format, institutional affiliation and use of non-technical language. These strategies can be applied to other prevention trials providing cost effective recruitment.
Cancer Control Research in Defined Populations: Design and Methodologic Considerations

Bruce Trock, Ph.D., Knut Ringen, Ph.D., Douglas Weed, M.D., Ph.D.

University of Pennsylvania Cancer Center
7 Silverstein
3400 Spruce St.
Philadelphia, PA 19104

This paper critically assesses problems in conducting Phase IV or defined population studies of cancer control interventions. Defined population studies (DPS) are intended to quantify the impact of interventions of demonstrated efficacy in stable, well-characterized populations. The objectives of DPS are to evaluate the performance of interventions and generalize the results to a target population, and identification of barriers to implementation (2,3). Current problems in the conduct of DPS are analyzed within the context of constraints on study design imposed by these objectives. In particular, the use of a randomized controlled trial design
for Phase IV studies is shown to involve problems in logistics, demonstration of a significant result, ability to generalize results, and ethical problems. Quasi-experimental studies using intermediate endpoints are proposed as a feasible alternative to randomized trials in Phase IV. Previously demonstrated intervention efficacy in a Phase III study helps to reduce the dangers of unmeasured sources of bias (1), and may also improve ability to detect a significant result.


Analysis of Barriers and Incentives to Mammographic Screening in The American Cancer Society (ACS) 1987 Texas Breast Screening Project (TBSP).


American Cancer Society, Texas Division, Inc., 2433 Ridgepoint Drive, Austin, Texas 78754.

Despite the ability of screening mammography to reduce breast cancer mortality, the procedure is not widely used by physicians due to the suspected radiation risk and its perceived low yield or ineffectiveness (1,3). Low levels of compliance by women with screening recommendations are due to cost (1,2), lack of public awareness, and other published barriers to wide acceptance of mammography (4,5). The ACS TBSP promoted low-cost ($50.00) mammographic screening at 300 participating screening centers following an intensive media campaign; 61,162 women presented for mammography. Each was given a 31-item questionnaire which
examined beliefs about breast cancer and screening-related risks and barriers. Data from 758 questionnaires are presented here. Although 60% had seen a physician in the preceding year, only 43% had ever had mammography. Of those women who had prior mammograms, 79% had only two or fewer exams. Low cost was identified as an important reason for having mammography in this project by 85% of the screenees. While 29% of screenees stated that their health insurer did not pay for screening mammograms, 58% did not know whether their insurance coverage included screening mammography. Only 49% said physicians' referrals influenced their decision to participate; 92% cited ACS publicity. These data indicate that public and physician education, coupled with a decrease in screening mammography cost, would substantially increase women's compliance with mammographic screening recommendations.

REFERENCES


USING A POPULATION-BASED CANCER REGISTRY
FOR RECRUITMENT IN A CANCER CONTROL STUDY:
THE WISCONSIN TAMOXIFEN STUDY

P. A. Newcomb, Ph.D.
R. R. Love, M.D.

University of Wisconsin
Clinical Cancer Center
1300 University Avenue
Madison, WI 53706
Cancer control investigations in the United States have not yet used population-based registries as a resource for recruitment. We are conducting a placebo-controlled, double-blind, randomized toxicity trial of tamoxifen in postmenopausal women with node negative breast cancer. This study is potentially a pilot for a major breast cancer chemosuppressive trial using this antiestrogen. To achieve our accrual goal of 140 in this single institution study, we have used the Wisconsin Cancer Reporting System, a population-based cancer registry. Registry information from the last nine years was used to identify 3,335 women who met the study criteria with respect to age, stage, and previous therapy. The vital status of identified women was confirmed using the state death records. For physicians reporting cases, rosters were prepared and sent to the physician with a cover letter and study description. The physicians were asked to update the lists and, if appropriate, to sign letters to possibly eligible and interested women. Thirty-four percent of women receiving a letter and study information from their doctors contacted the study office about participation. One year from its initiation, 100 women are entered on study and we project complete accrual in five to six months. This successful use of a population-based cancer registry illustrates an efficient recruitment method which could be modified for other cancer control/chemoprevention trials.
SELECTED POSTERS

These abstracts will be published in the journal Preventive Medicine, Vol. 17, No. 2, 1988.
WHAT IS SAFE SEX? James J. Goedert, M.D.
National Cancer Institute, Bethesda, Maryland 20892

Existing "safe (or safer) sex" guidelines either prohibit intercourse for all or advise measures that are not entirely safe, such as use of condoms. However, rational, scientific, and truly safe standards can be defined by the human immunodeficiency virus (HIV) status of the subject and his/her partner (1). A monogamous couple proven to be HIV negative-negative can engage in unprotected sexual contact of any kind, provided that outside risks (such as parenteral drug abuse) or partners have been eliminated for at least six months. A couple proven to be positive-positive must not have sex with HIV-negative or HIV-unknown partners but may themselves have intercourse if they use effective birth control to prevent HIV infection of babies. Safe sex standards must be stringent, not to exceed mutual masturbation, for HIV-discordant (positive-negative) and HIV-unknown couples. Fortunately, HIV-discordant couples are relatively uncommon, and most HIV-unknown couples can be tested and recategorized to the more lenient positive-positive or negative-negative standards. The HIV antibody test is an extremely sensitive and specific
tool that has been used with few adverse consequences in more than 10
million Americans (2). Now is the time to minimize the fear and
eliminate the risk of transmitting HIV to loved ones by urging universal
voluntary testing and by developing HIV-defined safe sex standards.

References: 1. Goedert JJ. What is safe sex? Suggested standards
linked to testing for human immunodeficiency virus. N Engl J Med
1987;316:1339-1342.
The Forsyth County Cervical Cancer Prevention Project

Mark Dignan, Ph.D., M.P.H., Larry Young, Ph.D., and Robert Michielutte, Ph.D., all of Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC 27103

Black women suffer mortality from cervical cancer at a rate over four times higher than for white women in Forsyth County, NC. This disparity provides the basic motivation for development of a five-year, NCI funded public health education project. The ultimate goal of the project is to reduce the death rates from cervical cancer in all women, and particularly to reduce the disparity in death rates between black and white women, by increasing rates of early detection of cervical cancer and its precursors by increasing Pap smears in the target population (black females age 18 and older residing in Forsyth County, NC).

The intervention will consist of two components, mass media education and a program of direct education through small groups. Development of the intervention will be guided by the Communication-Behavior Change (CBC) model. Focus groups, applied to development as well as review of message prototypes, will be used to insure that content and image are appropriate for the target population. Messages
will be produced for print and electronic media.

Evaluation will include both qualitative and quantitative measures. Data will be collected from black and white women residing in Forsyth County, NC and a comparable control county. Qualitative evaluation data will be collected by interviews. Quantitative evaluation to develop an estimate of efficacy of the program as a whole, will be carried overall by pre and post random-digit-dialed telephone surveys.


The Forsyth County Cervical Cancer Prevention Project

Mark Dignan, Ph.D., M.P.H, Department of Family and Community Medicine, Bowman Gray School of Medicine

Larry Young, Ph.D., Section on Medical Psychology, Bowman Gray School of Medicine

Robert Michielutte, Ph.D., Department of Family and Community Medicine, Bowman Gray School of Medicine

(Address for all authors)

300 South Hawthorne Rd.
Winston-Salem, NC 27103
PERSONAL, SOCIAL AND HEALTH CARE SYSTEM FACTORS AND STAGE OF DISEASE AT THE DIAGNOSIS OF COLORECTAL CANCER

J.M. Birdsell, B.Sc.N., M.Sc.
Project Co-ordinator
Steve Fonyo Cancer Prevention Program
Alberta Cancer Board
1331 29th Street N.W.
Calgary, Alberta
T2N 4N2

In an effort to identify factors contributing to a late diagnosis of colorectal cancer, patients in Southern Alberta were interviewed to determine if early stage and late stage cases differed on any of six dimensions of an illness behaviour model. Forty seven males and thirty three females diagnosed in 1985/1986 were interviewed in their homes. Information was collected on six areas from Cummings Illness Behaviour Model\(^1\): demographics, social network, attitudes toward health care, health care system variables such as doctor visits, knowledge about cancer and perceived health threat. Logistic regression was used to assess variables within each of the six areas and was then used to assess the full model including variables from all six areas. In a single area logistic regression, factors which significantly
contributed to predicting a late stage diagnosis (using remove and enter limits of .15 and .10 respectively) were attribution of symptoms to causes other than cancer, higher knowledge level about Pap tests, lower knowledge level about hemoccult tests, more visits to a general practitioner prior to diagnosis, more friends, neighbours and ministers in their support network and a lower perceived level of tangible aid. In the full model logistic regression, the only two factors remaining in the model after adjusting for effects of the others were the tendency of late stage patients to attribute the cause of symptoms to something other than cancer (perceived health threat) and their increased number of visits to the general practitioner before being diagnosed (health care system). A multiple causation model was an instructive approach to studying this problem as the results of the full model multiple logistic regression was somewhat different than the single area analysis.

THE STEVE FONYO CANCER PREVENTION PROGRAM: A DEMONSTRATION PROJECT IN FOUR ALBERTA CITIES

J.M. Birdsell, B.Sc.N., M.Sc.*
McGregor, S.E., B.Sc., M.Sc.*

* Department of Epidemiology and Preventive Oncology
Alberta Cancer Board
1331 29th Street N.W.
Calgary, Alberta
T2N 4N2

Hill, G.B., M.B., Ch.B., M.Sc.
Formerly with the Alberta Cancer Board
Presently:
Professor
Department of Epidemiology and Biostatistics
McGill University
1020 Pine Street West
Montreal, Quebec
H3A 1A2

A Cancer Prevention Demonstration Program began in Alberta in early 1987. The program is taking place in four Alberta cities whose population totals 140,000. This program is being done collaboratively by the Cancer Authority in the province and the Boards of Health in the four cities. The objectives of the program are:

1. To demonstrate the feasibility of the Cancer Board's involvement in community prevention programs.
2. To determine the most effective approach to risk reduction and early detection in the community setting.

3. To evaluate compliance with such programs and their efficiency in relation to cost.

4. To compare the efficacy of risk related individual intervention (personal counselling and individualized mailed information) in reducing the prevalence of modifiable risk factors and increasing the prevalence of behaviour favouring early detection.

The two interventions being used are based on an individual intervention approach and a community organization approach. A factorial design is being used so that the independent and interactional effects of the two approaches can be assessed. In the two cities with the individual intervention program, program staff will go door-to-door, offering risk assessment questionnaires to all individuals in the target age range (35-64). Program offerings from that point will depend on the individuals' risk appraisal. In the two cities with the community organization, community organization strategies are being used, as well as social marketing approaches to plan and deliver a public education program aimed at prevention and early detection.
Breast Abnormality Detection: breast self-examiners versus nurse examiners

Cornelia J Baines MD., MSc.
Ted Krasowski MSc.

NCIC Epidemiology Unit
Dept. of Preventive Medicine & Biostatistics
University of Toronto
12 Queen's Park Crescent West
Toronto, Ontario
Canada
M5S 1A8
Breast abnormality detection: breast self-examiners versus nurse-examiners

Cornelia J. Baines and Ted Krasowski

Proxy estimates of sensitivity, specificity and predictive value of breast self-examination (BSE) were developed and compared to levels of BSE competence in over 40,000 women.

Women attending their third screening visit in the National Breast Screening Study (2) were stratified according to their BSE competence score which was the unweighted sum of nine BSE components (1). Scores of 7-9 were good, 4-6 adequate and 0-3 poor. The women's reports of finding a breast lump were compared, side-specifically, to the findings of expert nurse-examiners on physical examination.

For good, adequate and poor BSE performers, Kappa (p < 0.001) expressing agreement between the examiners was 0.113, 0.107 and 0.076 (right) and 0.133, 0.105 and 0.079 (left) respectively. Proxy sensitivity was highest (right and left respectively) in good (0.088 and 0.110) and lowest (0.056 and 0.061) in poor performers. Mean specificity (0.99) and positive predictive value (0.45) were highest in poor performers.

Clearly good scorers show a higher (though still very poor) level of agreement with the clinical examiner and higher "sensitivity" than poor scorers.

References
SMOKESCREEN: A STUDY DESIGN

Patricia O'Keefe, R.N., B.S.N.* and Marilyn Halper, MPH**

*Kriser Lung Cancer Center 55 East 34 Street
              New York, NY 10016
**PMI/Strang Clinic 55 East 34 Street
              New York, NY 10016

The National Lung Program experience demonstrates the potential of detecting early stage lung cancers through screening heavy cigarette smokers with chest x-rays(1). The aim of our project is to evaluate biochemical tests in the prediction and early detection of lung cancer. These tests measure an isozyme of glutathione transferase using trans-stilbene oxide (GT-tSBO) as substrate, adenosine diphosphateribosyl transferase (ADPRT) and other biochemical markers (2,3). GT-tSBO has been inversely associated with lung cancer risk among persons who smoke(3). The epidemiologic risk factors family history, diet, occupational exposure and smoking history are incorporated into the design because of their importance in identification of lung cancer risk and as potential correlates of the biochemical markers. Three thousand heavy smokers over the age of 55 will be screened
annually for a period of three to five years with a PA chest x-ray and biochemical markers. The study will have at least 90% power to detect the estimated contribution of the biochemical markers in the identification of lung cancer for this high risk cohort. The purpose of this abstract is to inform the ASPO members of the study design and goals.


RELATIONSHIP OF MONONUCLEAR ORNITHINE DECARBOXYLASE TO ADENOSINE
DIPHOSPHATE RIBOSYL TRANSFERASE: IMPLICATIONS FOR IMMUNE
SUPPRESSION BY TUMOR BURDEN


*PMI/Strang Clinic, 55 East 34th Street, New York, NY 10016
**University of Lund, Wallenberg Laboratory, Division of Molecular Ecogenetics, Box 7031, S-220 07 Lund 7, Sweden
*** David B. Kriser Lung Cancer Center, 55 E 34th Street, New York, NY 10016
This study was designed to test the relationship between ornithine decarboxylase (ODC) and adenosine diphosphate ribosyl transferase (ADPRT) in human mononuclear leukocytes (HML), and their application to the study of immune response (2). We have correlated ODC levels (4) in unstimulated cells with their proliferative status ([3H]-Thymidine incorporation; \( r = 0.57, p = 0.02, n = 17 \)). In further samples \((n = 20)\), multivariate analysis related unstimulated ODC to a function of constitutive ADPRT, \( H_2O_2 \)-activated ADPRT \((1,5)\), and their separate interactions with age and gender \((R^2 = 0.68, p = 0.004)\). In HML stimulated with phytohemagglutinin (PHA) or pokeweed mitogen (PWM), ODC correlated significantly with both constitutive and \( H_2O_2 \)-activated ADPRT in non-smokers \((e.g. PWM-induced ODC/Constitutive ADPRT: \( r = 0.71, p = 0.0015, n = 18 \)); in smokers the correlation was significant between PHA-induced ODC and constitutive ADPRT \((r = 0.56, p = 0.024, n = 18)\). There is, therefore, a significant relationship between ODC and ADPRT measurements: this strongly suggests that ADPRT relates to the proliferative capacity of HML. Since that capacity, and other lymphocyte reactions, are affected by tumor factors (4), we are studying ODC and ADPRT assays in relation to immune responsiveness, with special reference to immune suppression, and the possibility of providing a screening test for the presence of tumor.
REFERENCES


FORMATION OF GLUTATHIONE DISULFIDE FOLLOWING TREATMENT OF HUMAN MONONUCLEAR LEUKOCYTES WITH HYDROGEN PEROXIDE REVEALS INTRAINDIVIDUAL DIFFERENCES IN RESPONSES TO OXIDATIVE STRESS

G.A. Doyle, Ph.D.* , R.W. Pero, Ph.D.** , D.B. Johnson, Ph.D.* , N. Raskin, M.D.*** , and D.G. Miller, M.D.*

*PMI/Strang Clinic, 55 East 34th Street, New York, NY 10016
**University of Lund, Wallenberg Laboratory, Division of MolecularEcogenetics, Box 7031, S-220 07 Lund 7, Sweden
***David B. Kriner Lung Cancer Center, 55 East 34th Street, New York, NY 10016

The rate of glutathione disulfide (GSSG) formation following exposure of cells to an oxidative agent is believed to reflect the extent of free radical-induced oxidative stress within those cells (3). Using human mononuclear leukocytes (HML) from peripheral blood samples, this study was undertaken to determine whether individuals vary in their responses to oxidative stress. This was achieved through determining the rate of GSSG formation.
following exposure to $H_2O_2$ (2). Treatment of HML with $H_2O_2$ resulted in the oxidation of intracellular reduced glutathione (GSH) to GSSG in a dose dependent manner. Following a one minute exposure of cells to $H_2O_2$ at 37°C in the presence of glucose, HML from individual to individual varied greatly as to the percent of GSH that was oxidized. Such variation was seen regardless of the concentration of $H_2O_2$ used. In the presence of 500 µM $H_2O_2$, anywhere from 8%-73% of the GSH was oxidized to GSSG. 100 µM $H_2O_2$ resulted in a 21%-60% oxidation. Furthermore, while the oxidation of GSH was dose dependent, concentrations of $H_2O_2$ required for maximal oxidation also varied from individual to individual (100 µM-500 µM). It therefore appears that individuals are not all equal in their responses to oxidative stress. Since oxidative stress is believed to be involved in carcinogenesis (1), intraindividual differences in glutathione oxidation by $H_2O_2$ could be a useful biochemical marker to study susceptibility to cancer. This is currently being pursued by our laboratory.
REFERENCES


ASSOCIATION BETWEEN DIESEL EXHAUST EXPOSURE AND MULTIPLE MYELOMA: AN EXAMPLE OF CONFOUNDING

Paolo Boffetta, M.D.; Steven D. Stellman, Ph.D.

American Cancer Society, 1180 Avenue of the Americas, New York, NY 10036, USA

In 1982 the American Cancer Society volunteers enrolled over 1,200,000 American women and men in a six years mortality prospective study. The subjects filled out a questionnaire on cancer risk factors; every two years their vital status is ascertained and death certificates for dead subjects are traced. An analysis on diesel exhaust exposure and two years mortality for different causes among 461,981 males aged 40-79 has been carried out, and the results will be published elsewhere (2). Among the causes of death that were associated (p<0.05) with diesel exhaust exposure in a crude analysis, multiple myeloma (MM, ICD-9 203) had not been previously reported (3). The crude relative risk (RR) was 2.1, and the 95% confidence interval (CI) was 1.2-3.9, (9 exposed and 37 unexposed deaths): they were not modified after controlling for age and smoking. The RR was
reduced by controlling for asbestos exposure to 1.3 (95% CI 0.6-2.7), this fact showed a confounding effect of asbestos: the result was not modified by controlling for coal and stone dusts, tar, pitch, or gasoline exhaust exposures. The RR for MM of asbestos exposure was 2.0 (95% CI 1.0-4.3, after controlling for age, smoking, and other occupational exposures), but the result is still preliminary. The evidence of an association between asbestos and MM derived from the literature is inconclusive (1), and further analysis from our study will be undertaken.


THE EFFECTS OF SINIGRIN AND INDOLE-3-CARBINOL ON DNA METHYLATION, O\textsuperscript{6}-METHYLGUANINE-DNA-TRANSMETHYLASE, AND 3\textsuperscript{H}-THYMIDINE INCORPORATION IN TARGET TISSUES OF NNK-INDUCED TUMORIGENESIS.

Mark A. Morse, Ph.D. and Fung-Lung Chung, Ph.D.

Section of Nucleic Acid Chemistry, Division of Chemical Carcinogenesis, American Health Foundation, Valhalla, New York 10595.

Glucosinolates and their hydrolysis products, widely distributed in cruciferous vegetables, have been found to possess significant antitumorigenic activity in some animal models (1). In order to evaluate the potential activity of the glucosinolate sinigrin and indole-3-carbinol (a product of glucobrassicin hydrolysis) on tumorogenesis induced by the tobacco-specific nitrosamine NNK, the effects of these compounds on NNK-induced DNA methylation, O\textsuperscript{6}-methylguanine-DNA-transmethylase activity, and 3\textsuperscript{H}-thymidine incorporation were examined in the liver, lung, and nasal mucosa of Fischer 344 rats. In all studies, rats were pretreated with control diets or diets containing sinigrin (0.003 mmole/g diet) or indole-3-carbinol (0.03 mmole/g diet) for
periods of 7-14 days. In the DNA methylation studies, pretreated rats were administered $^3\text{H-CH}_3$-NNK s.c. (0.6 mg/kg, 0.12 Ci/m mole) for four consecutive days. Pretreatment with sinigrin decreased 7-methylguanine levels in hepatic DNA by 30% compared to control. However, no effects on 7-methylguanine levels were observed in lung or nasal mucosa following sinigrin pretreatment. Pretreatment with indole-3-carbinol increased hepatic 7-methylguanine levels by 33% while resulting in decreased 7-methylguanine levels in DNA of both lung and nasal mucosa. The effects on hepatic 7-methylguanine levels are consistent with previous results in which sinigrin pretreatment decreased demethylation of NNK while indole-3-carbinol increased demethylation of NNK in hepatic microsomal preparations (2). $O^6$-Methylguanine-DNA-transmethylase activity was not affected in the target tissues of rats pretreated with sinigrin or indole-3-carbinol. The effects of these compounds on cell proliferation was assessed by their effects on $^3\text{H}$-thymidine incorporation. Sinigrin was found to decrease hepatic $^3\text{H}$-thymidine incorporation by more than 30%.

These results suggest that sinigrin may act as an inhibitor of NNK-induced hepatic tumors, while indole-3-carbinol may enhance NNK tumorigenicity in liver and inhibit NNK tumorigenicity in lung and nasal mucosa.
References
